Natural Product (NP) Details
General Information of the NP (ID: NP3247) | |||||
---|---|---|---|---|---|
Name |
Artemisinin
|
||||
Synonyms |
Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
Click to Show/Hide
|
||||
Species Origin | Artemisia annua ... | Click to Show/Hide | |||
Artemisia annua | |||||
Disease | Malaria [ICD-11: 1F40] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H22O5
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C
|
||||
InChI |
1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
|
||||
InChIKey |
BLUAFEHZUWYNDE-NNWCWBAJSA-N
|
||||
CAS Number |
CAS 63968-64-9
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
25-methoxyl-dammarane-3beta, 12beta, 20-triol | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | PRSS50 | Molecule Info | ||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
ER7530 | Breast cancer | Homo sapiens | ||||
Experimental
Result(s) |
25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression. | |||||
Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Eca-109 | CVCL_6898 | Esophageal squamous cell carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta-catenin signaling pathway. | |||||
Halofuginone | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CDKN1B | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
A-375 | CVCL_0132 | Amelanotic melanoma | Homo sapiens | |||
MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | HCT116 cells (5*106 cells per mouse) were suspended in PBS and inoculated subcutaneously into the left flank of each female BALB/c nude mice. | |||||
Experimental
Result(s) |
Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. | |||||
Sodium butyrate | Acute myeloid leukemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Biological
Regulation |
Up-regulation | Apoptosis | ||||
In-vitro Model | MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
Experimental
Result(s) |
DHA in combination with butyric acid acts synergistically at low doses. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Plasmodium dihydroorotate dehydrogenase (Malaria DHOdehase) | Molecule Info | [1] | |
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) | Molecule Info | [1] | ||
KEGG Pathway | Pyrimidine metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
Pathwhiz Pathway | Pyrimidine Metabolism | Click to Show/Hide | ||
Reactome | Pyrimidine biosynthesis | Click to Show/Hide | ||
WikiPathways | Metabolism of nucleotides | Click to Show/Hide |






